BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Cancer Treatment - geneonline.com
  300+ employees from 33 nations will cycle to advance cancer research, celebrating 12 years of C2C4C - Bristol Myers Squibb (BMS)
  Bristol Myers Squibb Announces Dividend - Yahoo Finance
  BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb - WSJ
  Bristol Myers CEO stays bullish on Cobenfy despite trial flop, signs of slowing momentum - Fierce Pharma
  Chutes ' Ladders— BMS banks on Wall Street vet for long-term strategy guidance - Fierce Biotech
  BioNTech and Bristol Myers Squibb Partner in $10 Billion Oncology Agreement Focused on Immunotherapy - geneonline.com
  Chris Shibutani, MD - Bristol Myers Squibb (BMS)